Upgrade to SI Premium - Free Trial

UBS Reiterates Buy Rating on Teva Pharma (TEVA) as Pipeline Opportunities Broaden

June 26, 2026 9:35 AM
UBS analyst Ashwani Verma reiterated a Buy rating and $42.00 price target on Teva Pharma (NYSE: TEVA).The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments